StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.46−0.03 (-0.11%)

Close on Nov 18, 2026Market cap $4.54BP/E –Yield –

Adaptive Biotechnologies operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Adaptive Biotechnologies's operating income for the twelve months ending Jun 30, 2026 was -$37.46M. For fiscal 2025 it was -$57.12M. The highest annual figure on record is -$44.48M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$57.12M–
FY2024Dec 31, 2024-$162.55M–
FY2023Dec 31, 2023-$227.04M–
FY2022Dec 31, 2022-$200.19M–
FY2021Dec 31, 2021-$208.97M–
FY2020Dec 31, 2020-$152.82M–
FY2019Dec 31, 2019-$78.39M–
FY2018Dec 31, 2018-$49.76M–
FY2017Dec 31, 2017-$44.48M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.77M–
Q1 FY2026Mar 31, 2026-$19.21M–
Q4 FY2025Dec 31, 2025-$12.77M–
Q3 FY2025Sep 30, 2025$10.29M–
Q2 FY2025Jun 30, 2025-$25.04M–
Q1 FY2025Mar 31, 2025-$29.60M–
Q4 FY2024Dec 31, 2024-$33.84M–
Q3 FY2024Sep 30, 2024-$32.63M–
Q2 FY2024Jun 30, 2024-$47.32M–
Q1 FY2024Mar 31, 2024-$48.76M–
Q4 FY2023Dec 31, 2023-$71.07M–
Q3 FY2023Sep 30, 2023-$50.96M–
Q2 FY2023Jun 30, 2023-$47.82M–
Q1 FY2023Mar 31, 2023-$57.19M–
Q4 FY2022Dec 31, 2022-$39.19M–
Q3 FY2022Sep 30, 2022-$45.43M–
Q2 FY2022Jun 30, 2022-$52.50M–
Q1 FY2022Mar 31, 2022-$63.07M–
Q4 FY2021Dec 31, 2021-$61.60M–
Q3 FY2021Sep 30, 2021-$56.33M–
Q2 FY2021Jun 30, 2021-$49.77M–
Q1 FY2021Mar 31, 2021-$41.28M–
Q4 FY2020Dec 31, 2020-$44.24M–
Q3 FY2020Sep 30, 2020-$37.05M–
Q2 FY2020Jun 30, 2020-$36.91M–
Q1 FY2020Mar 31, 2020-$34.62M–
Q4 FY2019Dec 31, 2019-$24.19M–
Q3 FY2019Sep 30, 2019-$18.05M–
Q2 FY2019Jun 30, 2019-$16.11M–
Q1 FY2019Mar 31, 2019-$20.05M–
Q4 FY2018Dec 31, 2018-$14.14M–
Q3 FY2018Sep 30, 2018-$9.16M–
Q2 FY2018Jun 30, 2018-$13.31M–

More Adaptive Biotechnologies figures

See a number that looks wrong?